바로가기메뉴

본문 바로가기 주메뉴 바로가기

Reference

1.

(2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome,

2.

(2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock,

3.

et al. Definition for sepsis and organ failure and guidelines for the use of innovative therapies for the use of innovative therapies in sepsis. Chest 1992,

4.

(2001) Efficacy and safety of recombinant human activated protein C for severe sepsis,

5.

(2001) Intensive insulin therapy in critically ill patients,

6.

(2006) Intensive insulin therapy in the medical ICU,

7.

(2004) Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US): a single-arm,, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis,

8.

(2001) Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome,

9.

(1997) Monocyte deactivation in septic patients: restoration by INF-gamma treatment,

10.

(2000) Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte,

11.

American College of Chest Physicians/Society of Critical Care Medicine. Consensus Conference definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992,

12.

(2003) The epidemiology of sepsis in the United States from 1979 through 2000,

13.

(2006) Management of sepsis,

14.

(2004) Corticosteroids for severe sepsis and septic shock: a systematic review and meta- analysis,

Tuberculosis & Respiratory Diseases